A panel of expert speakers from across the Nordic region will outline current policy and regulations governing precision medicine, and the initiatives being implemented to further advance its implementation, in their specific countries. A panel discussion will then explore some of the following issues:
- How can flexibility be built into policy development to enable regulatory frameworks to adapt and innovate as research and technology progresses?
- To what extent can, or should, national regulations be harmonised, or common European policies adopted to facilitate and advance precision medicine?
- Assessing where time, energy and investment should be best focused in order to implement precision medicine into the clinical setting
- Determining the extent to which specific provision for scientific research within General Data Protection Regulation (GDPR) differs across European countries:
- what frameworks, principles and norms have so far been developed to ensure an ethical approach to data sharing in health research?
- Managing the balance between patient privacy rights and the benefits of data-sharing
- understanding patients’ expectations of research and the societal benefits and value from it
- how do we generate and maintain patient trust with regards to their personal information?
- Assessing the impact of AI and digital healthcare on data governance requirements
These focused, interactive sessions give you the opportunity to discuss a key topic of interest to you in a more participative format. Each session will be led by a facilitator who will lead the discussion and encourage maximum debate and sharing of ideas.
This workshop will explore how we can take advantage of national and international funding schemes as well as Public-Private Partnerships & collaborations. What are the challenges and how can they be overcome?
This session, led by Apotekarsocieteten, the Swedish Pharmaceutical Society, will comprise a series of short presentations on drug development for precision medicine, followed by a panel debate.
The Copenhagen Hospital Biobank and The Danish Blood Donor Study – Two Large-Scale National Biobanks for Health Research
- Exploring the perception of “value” and the key criteria on which investment and funding decisions are made:
- to what extent can evidence-based testing and technologies facilitate these decisions?
- Examining how the disease and drug classification and reimbursement system could be changed to enable a broader, biological approach: how does this differ across different European countries?
- Developing effective reimbursement mechanisms to meet the requirements of the payer and “justify” precision medicine
- Finding an effective balance between value economics and optimum patient care
Patient’s Perspective: Patients as a Driving-Force to Advance Precision Medicine
- Examining the key issues currently affecting data availability, affordability and quality
- Assessing what needs to be done to monitor this and ensure data gathered is as usable as possible:
- Identifying which technologies can facilitate the flow of health data
- Identifying the key challenges in multi-omics data utilisation and possible solutions
- Assembling the right “toolbox” for optimum data integration and analysis:
- developing robust and transparent bioinformatic pipelines to provide timely and useful clinical information
- using new data analysis tools to gain better insights from the information available
- techniques for reporting the findings in a coherent and useful way
- Exploring new methods for integrating genetic data from different sources to find the meaningful overlap:
- selecting the most relevant variables from different -omics datasets and samples
- techniques for extracting common information from different datasets for the same patients and classifying patients
- Successfully translating multi-omics data into clinically actionable biomarkers
- Exploring how the increasing volume of behavioural and lifestyle data can be integrated appropriately with clinical data:
- how to utilise patient led self-care data in healthcare - Finnish example
- Exploring the latest innovations in mobile, smart, cloud and self-diagnostic technologies for obtaining patient data and insights for use as digital biomarkers
- Identifying the challenges to be overcome in using digital biomarkers and possible solutions:
- reliability of technology and results
- standardisation of results from patient technology and in a clinical setting
- data privacy issues
- Successfully leveraging the information generated to track trends and patterns for individuals and populations:
- examining what tools are needed to effectively integrate e-health technology into clinical practice
- assessing the implications for healthcare systems of patient self-management technologies and increased patient empowerment
- Demonstrating the use of health-tech and patient-driven technology as diagnostic tools in practice
- Determining the costs and time-scales of using functional testing and analysis compared to genomic approaches
- To what extent can in-vitro methods using patient-derived calls (PDCs) deliver an appropriate response? Do they effectively mirror the patient and likely tumour mutation?
- Exploring recent advances in modelling organoids and their likely implementation into clinical practice
- Assessing the infrastructure, data and technology changes required to current healthcare systems in order to deliver a precision medicine approach
- Research / Clinic interaction: Exploring how to translate broad genomic and multi-omic profiling data into actionable insights that can be used in clinics
- Discovering innovative ways of reorganising healthcare systems with limited resources
- Assessing the effectiveness of clinical trials and how they can facilitate precision medicine in practice
- Assessing how the role of HCPs will change in future and how they will need to adapt to deliver healthcare, including digital health and precision medicine
- Effectively managing increasing patient empowerment
- Communicating and convincing HCPs of the validity and potential of new personalised treatments and therapies
- Training HCPs to analyse and effectively use the data available to them